JP2017537893A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537893A5
JP2017537893A5 JP2017523295A JP2017523295A JP2017537893A5 JP 2017537893 A5 JP2017537893 A5 JP 2017537893A5 JP 2017523295 A JP2017523295 A JP 2017523295A JP 2017523295 A JP2017523295 A JP 2017523295A JP 2017537893 A5 JP2017537893 A5 JP 2017537893A5
Authority
JP
Japan
Prior art keywords
antibody
adc
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017523295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537893A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058389 external-priority patent/WO2016070089A2/en
Publication of JP2017537893A publication Critical patent/JP2017537893A/ja
Publication of JP2017537893A5 publication Critical patent/JP2017537893A5/ja
Withdrawn legal-status Critical Current

Links

JP2017523295A 2014-10-31 2015-10-30 抗cs1抗体および抗体薬結合体 Withdrawn JP2017537893A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073824P 2014-10-31 2014-10-31
US62/073,824 2014-10-31
PCT/US2015/058389 WO2016070089A2 (en) 2014-10-31 2015-10-30 Anti-cs1 antibodies and antibody drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020040783A Division JP2020111583A (ja) 2014-10-31 2020-03-10 抗cs1抗体および抗体薬結合体

Publications (2)

Publication Number Publication Date
JP2017537893A JP2017537893A (ja) 2017-12-21
JP2017537893A5 true JP2017537893A5 (enExample) 2018-07-26

Family

ID=54478286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523295A Withdrawn JP2017537893A (ja) 2014-10-31 2015-10-30 抗cs1抗体および抗体薬結合体
JP2020040783A Pending JP2020111583A (ja) 2014-10-31 2020-03-10 抗cs1抗体および抗体薬結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020040783A Pending JP2020111583A (ja) 2014-10-31 2020-03-10 抗cs1抗体および抗体薬結合体

Country Status (10)

Country Link
US (2) US10011657B2 (enExample)
EP (1) EP3212668B1 (enExample)
JP (2) JP2017537893A (enExample)
AU (1) AU2015339012B2 (enExample)
BR (1) BR112017008945A2 (enExample)
CA (1) CA2966005C (enExample)
ES (1) ES2832711T3 (enExample)
IL (1) IL251938A0 (enExample)
SG (1) SG11201703446RA (enExample)
WO (1) WO2016070089A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
PL3313528T3 (pl) * 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
HK1254836A1 (zh) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag 抗-ror1抗体
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
LT3512547T (lt) 2016-09-14 2021-01-11 Abbvie Biotherapeutics Inc. Antikūnai prieš pd-1
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
US20200023071A1 (en) * 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
CN111670200A (zh) * 2017-11-29 2020-09-15 美真达治疗公司 用于耗尽cd2+细胞的组合物和方法
KR20200128518A (ko) 2018-02-23 2020-11-13 바이사이클티엑스 리미티드 다량체성 비사이클릭 펩타이드 리간드
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CN111001012A (zh) * 2018-10-19 2020-04-14 四川百利药业有限责任公司 一种亲水碳酸酯型抗体偶联药物
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20230241241A1 (en) * 2020-06-19 2023-08-03 Hangzhou Dac Biotech Co., Ltd. Conjugates of a cell-binding molecule with camptothecin analogs
KR20230074119A (ko) 2020-08-03 2023-05-26 바이사이클티엑스 리미티드 펩타이드 기반 링커
AU2020479745A1 (en) * 2020-12-04 2023-07-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
JP7561279B2 (ja) * 2020-12-18 2024-10-03 シャンハイ フダン-チャンジャン バイオ-ファーマシューティカル カンパニー リミテッド Trop2を標的とする抗体薬物複合体、その製造方法及び使用
EP4265274B1 (en) * 2020-12-18 2025-03-19 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
CN113181373B (zh) * 2021-05-10 2024-03-01 深圳安特生物医药科技有限公司 一种抗体药物偶联制剂及其制备方法和应用
US20250108124A1 (en) * 2021-05-19 2025-04-03 Biohaven Therapeutics Ltd. Antibody drug conjugates using mates technology for delivering cytotoxic agents
AU2022388735A1 (en) 2021-11-09 2024-05-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136841A (en) 1873-03-18 Improvement in cotton-presses
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
CN101415679A (zh) 2006-02-02 2009-04-22 辛塔佳有限公司 水溶性cc-1065类似物及其缀合物
PT2068874E (pt) 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ,インコーポレイティド 多発性硬化症を処置するための抗cs1抗体を用いる組成物および方法
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
US8399512B2 (en) 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
JP6099976B2 (ja) 2009-04-01 2017-03-29 ジェネンテック, インコーポレイテッド 抗FcRH5抗体および免疫接合体ならびに使用方法
KR20120057588A (ko) 2009-05-28 2012-06-05 메르사나 테라퓨틱스, 인코포레이티드 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP3228325A1 (en) 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
MX2014006739A (es) 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
WO2013130093A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
NO2760138T3 (enExample) * 2012-10-01 2018-08-04
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates

Similar Documents

Publication Publication Date Title
JP2017537893A5 (enExample)
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
KR102923527B1 (ko) 생체활성 분자 접합체, 이의 제조 방법 및 용도
CN106029083B (zh) 亲水性抗体-药物偶联物
CN115990269B (zh) 依沙替康衍生物及其连接子-负载物和缀合物
JP7244987B2 (ja) 多剤抗体薬物コンジュゲート
US20230073692A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2023082096A (ja) エリブリンをベースとする抗体-薬物コンジュゲート及び使用方法
TW202010498A (zh) 喜樹鹼肽結合物
KR102329024B1 (ko) 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
US11071788B2 (en) Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
JP2019532056A5 (enExample)
JP2020509027A5 (enExample)
EA038512B1 (ru) Конъюгаты майтанзиноидов и их терапевтическое применение
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
AU2016232839A1 (en) CD48 antibodies and conjugates thereof
JP6936399B2 (ja) 抗sez6抗体薬物コンジュゲート及び使用方法
JP2025505809A (ja) 抗体-エリブリン又はその誘導体の複合体、その中間体、製造方法、医薬組成物及び使用
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途
CN120923577A (zh) 大环类药物偶联物及其制备方法和用途
WO2026011073A1 (en) Antibody drug conjugates
CN120774988A (zh) 一种连接子、抗体药物偶联物及其制备方法
CN120957758A (zh) 大环化合物及其制备方法和用途
HK40097386A (zh) 多药抗体药物偶联物